Brief: GSK Presents Positive Data For Jideytro In First-Line Ros1-Positive NSCLC
14/09/2026 07:28
BRIEF-GSK Presents Positive Data For Jideytro In First-Line Ros1-Positive NSCLC Sept 14 (Reuters) - GSK plc GSK.L:
GSK PLC - JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC
GSK - PRESENTS POSITIVE DATA FOR JIDEYTRO IN FIRST-LINE ROS1-POSITIVE NSCLC
GSK - JIDEYTRO ACHIEVES 94% OBJECTIVE RESPONSE RATE AT 15.2 MONTHS FOLLOW-UP
GSK - PLANS US REGULATORY SUBMISSION FOR JIDEYTRO IN 2026
GSK - 90% OF PATIENTS PROGRESSION FREE AT 12 MONTHS, MEDIAN PFS NOT YET REACHED
GSK - 70% OF PATIENTS WITH BRAIN METASTASES ACHIEVE COMPLETE CLEARANCE OF DETECTABLE TUMOURS
Source text: ID:nRSN5204Ua
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))